Can Myopia Be Reversed?
What Actually Works in 2026
Short answer: No — once the eye has physically grown longer, that length cannot be reversed. But myopia progression — how fast it keeps growing — absolutely can be slowed, and in many children, nearly stopped with the right treatment.
Why myopia cannot be reversed
Myopia is caused by the eyeball growing too long from front to back — a measurement called axial length. When light enters a longer eye, it focuses in front of the retina instead of on it, making distant objects blurry.
Axial length is a physical dimension of the eyeball. Once an eye grows to 25mm, it does not shrink back to 23mm. The structural elongation is permanent. This is confirmed by every major published cohort study and is the reason the IMI 2025 Digest frames myopia management as prevention of further growth, not reversal of past growth.
Eye exercises, vision therapy, special diets, pinhole glasses, and "natural cure" claims all fail for the same reason: none of them can change the physical length of the eyeball. They may reduce eye strain or improve focusing flexibility, but they do not alter axial length. No controlled trial has shown otherwise.
What CAN be done: slowing progression
While reversal is not possible, slowing the rate of progression is one of the most evidence-rich areas in modern optometry. Several treatments have been shown in large randomised controlled trials to reduce axial elongation by 30–67% compared to untreated controls.
| Treatment | AL reduction vs untreated | Key trial | Regulatory status |
|---|---|---|---|
| MiSight® 1 day | ~55% at 3 years | Chamberlain et al. 2019 | FDA-approved (age 8–12) |
| Stellest® / HAL lenses | ~67% at 2 years | Bao et al. 2022 | Not approved in US |
| Orthokeratology | ~50% (meta-analysis) | Multiple RCTs | Off-label for myopia control |
| Atropine 0.05% | ~58% at 3 years | LAMP study (Yam et al. 2019) | Off-label (compounded) |
| Atropine 0.01% | ~30% at 2 years | ATOM2 (Chia et al. 2012) | Off-label (compounded) |
| Outdoor time ≥2hr/day | Delays onset; limited effect once established | Strong observational data | N/A |
Efficacy values represent change in axial elongation vs untreated at ~2-year RCT endpoints. Individual outcomes vary. Trial populations differ from every patient.
The clinical insight from IMI 2025: the goal is not to reverse the eye that has already grown — it is to prevent it from growing to lengths where serious complications begin. Keeping axial length below 26mm over a lifetime is associated with meaningfully lower risk of myopic maculopathy, retinal detachment, and glaucoma.
Does LASIK reverse myopia?
LASIK, PRK, and SMILE correct the optical consequence of myopia by reshaping the cornea — but they do not change axial length. After LASIK your eye is still the same physical length it was before. The structural risk factors associated with a long eye (retinal detachment, maculopathy) remain unchanged.
A person with a corrected prescription of plano after LASIK still has the same lifetime retinal risk profile as before surgery if their pre-LASIK axial length was in the high range. LASIK is a correction, not a cure.
On r/myopia, one of the most common posts is: "I've been doing eye exercises for 3 months and my vision feels noticeably clearer — is my myopia reversing?"
What's actually happening: Eye exercises can improve accommodative flexibility and reduce ciliary muscle fatigue, making vision feel more comfortable and sometimes temporarily sharper. This is a real benefit for eye strain. It is not the same as reducing axial length. The only way to know if myopia is genuinely stabilising is to measure axial length at two visits separated by at least 12 months.
Why starting before age 10 changes the lifetime outcome
Myopia itself cannot be reversed — but when you start treatment dramatically affects the final outcome. Research from Tideman et al. (Acta Ophthalmologica 2018) shows that age of onset is the strongest single predictor of reaching high myopia (≥−6.00D) by adulthood.
The critical window: Children who develop myopia before age 10 have the fastest axial growth rates during the years when treatment efficacy is highest. Even delaying treatment by 6–12 months in this age group meaningfully increases lifetime myopia burden — because those are the fastest-growing months, and every 0.1mm of axial elongation prevented compounds over years.
A concrete example: A 7-year-old starting at −1.00D who receives no treatment may reach −7.00D by age 18 (high myopia, significant structural risk). The same child starting treatment at −1.00D with 60% efficacy could finish at approximately −3.50D — a difference of 3.5 diopters and substantially lower lifetime risk of retinal detachment, maculopathy, and glaucoma. The treatment didn't reverse anything — it prevented future elongation from happening.
This is why the IMI 2025 consensus guidelines shifted from "treat fast progressors" to "treat at diagnosis" in young children. The long-term stakes are structural eye health, not just the prescription number. Waiting for progression to accelerate before acting means missing the window where treatment has the most impact per year invested.
See: When should a child start myopia treatment? for the full clinical decision framework.
The bottom line
- Myopia cannot be reversed once axial elongation has occurred. No supplement, exercise, device, or lifestyle change changes the physical length of the eye.
- Myopia progression can be meaningfully slowed (30–67%) with evidence-based treatments available now.
- The earlier treatment starts, the more total axial elongation is prevented — and that cumulative difference determines lifetime risk of serious eye disease.
- If a child's myopia is progressing rapidly, the clinically appropriate response is a myopia control intervention — not watchful waiting.
Is your child's myopia still progressing?
Enter age and two axial length measurements to calculate the annual progression rate and see whether it meets the threshold for treatment review.
Check progression rate →Free · No login · Under 30 seconds
This page is for educational purposes and does not constitute medical advice. MyopiaTracker is a decision-support tool — not a diagnostic device. MiSight® is a registered trademark of The Cooper Companies. Stellest® is a registered trademark of Essilor International. MiyoSmart® is a registered trademark of Hoya Corporation. Treatment availability and regulatory approval vary by country. Consult a qualified optometrist or ophthalmologist for personalised advice.